AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced and held academic positions in several countries including Switzerland, India, Iran, Germany Canada and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.


ABOUT THIS REPORT

The original report on Cardiovascular Drug Delivery appeared as a chapter in the author's Drug Delivery Systems published by Decision Resources Inc in 1998. The second edition was published by Informa Pharmaceuticals after detaching Cancer Drug Delivery and Central Nervous System Drug Delivery. Cardiovascular Drug Delivery has now been detached, expanded and updated to be issued as separate publications by Jain PharmaBiotech.

December 2019
Copyright © 2019 by
Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland
Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.
# Table of Contents

0. Executive Summary ........................................................................................................... 10

1. Cardiovascular Diseases .................................................................................................. 12
   Introduction ....................................................................................................................... 12
   History of cardiovascular drug delivery ............................................................................. 12
   Overview of cardiovascular disease ................................................................................ 13
   Coronary artery disease .................................................................................................... 13
   Angina pectoris ................................................................................................................ 13
   Myocardial infarction ......................................................................................................... 13
   Limitations of current therapies for myocardial ischemic disease .................................... 14
   Cardiomyopathies ............................................................................................................ 14
   Cardiac arrhythmias ......................................................................................................... 14
   Congestive heart failure .................................................................................................... 15
   Peripheral arterial disease ............................................................................................... 15
   Current management ....................................................................................................... 16
   Atherosclerosis .............................................................................................................. 16
   The endothelium as a target for cardiovascular therapeutics .......................................... 16

Molecular cardiology .......................................................................................................... 16
   Cardiogenomics ............................................................................................................... 17
   Cardioproteomics ........................................................................................................... 17

Personalized cardiology ..................................................................................................... 18
   Pharmacogenomics of cardiovascular disorders ............................................................. 18
   Modifying the genetic risk for myocardial infarction ....................................................... 18
   Management of heart failure ............................................................................................ 19
   Management of hypertension ............................................................................................ 19
   Pharmacogenomics of diuretic drugs .............................................................................. 20
   Pharmacogenomics of ACE inhibitors ........................................................................... 20
   Management of hypertension by personalized approach ............................................... 20
   Pharmacogenetics of lipid-lowering therapies ................................................................. 21
   Polymorphisms in genes involved in cholesterol metabolism ......................................... 21
   Role of eNOS gene polymorphisms ................................................................................ 21

Important advances in cardiovascular therapeutics ............................................................ 22
   Drug delivery, biotechnology and the cardiovascular system .......................................... 22
   Role of cardiovascular imaging in cardiovascular therapeutics ...................................... 23
   Biologic therapeutics for cardiovascular disorders ......................................................... 23
   Chronopharmacotherapy of cardiovascular diseases ...................................................... 23

2. Methods for Drug Delivery to the Cardiovascular System ............................................. 26
   Introduction ..................................................................................................................... 26
   Routes of drug delivery to the cardiovascular system ..................................................... 26
   Local administration of drugs to the cardiovascular system .......................................... 26
      Intramyocardial drug delivery ....................................................................................... 26
      Drug delivery via coronary venous system .................................................................... 27
      Intrapericardial drug delivery ...................................................................................... 27

   Formulations for drug delivery to the cardiovascular system ......................................... 28
      Sustained and controlled release ................................................................................ 28
      Programming the release at a defined time .................................................................... 29
      Dosage formulation of calcium channel blockers ....................................................... 29
      Sustained and controlled release verapamil ................................................................. 29
      Methods of administration of proteins and peptides .................................................... 29
      Delivery of peptides by subcutaneous injection ............................................................ 30
      Depot formulations and implants ............................................................................... 30
      Poly(ethylene glycol) technology ................................................................................ 30
      Liposomes for cardiovascular drug delivery .................................................................. 31
      Microencapsulation for protein delivery ....................................................................... 31
      Localized delivery of biomaterials for tissue engineering ............................................. 31
      Local delivery of proteins and peptides ...................................................................... 31

   Monoclonal antibodies for cardiovascular disorders ...................................................... 33
      Abciximab .................................................................................................................... 34
      Canakinumab .............................................................................................................. 34
      PCSK9 MAbs .............................................................................................................. 34

   DDS to improve systemic delivery of cardiovascular drugs ............................................ 35
   Nanotechnology-based drug delivery .............................................................................. 35
      Controlled delivery of nanoparticles to injured vasculature ........................................ 36
      Nanoparticles for cardiovascular imaging and targeted drug delivery ....................... 37
      Nanofiber-based scaffolds with drug-release properties .............................................. 37

   Targeted drug delivery to the cardiovascular system ...................................................... 37
3. Cell Therapy for Cardiovascular Disorders .................................................. 68

   Introduction .................................................................................................. 68
   Inducing the proliferation of cardiomyocytes ............................................... 68
   Role of stem cells in repair of the heart .............................................................. 68
   Cell-mediated immune modulation for chronic heart disease ...................... 68
   Cell therapy for atherosclerotic coronary artery disease .............................. 69
   Transplantation of myoblasts for myocardial infarction ............................... 69
   MyoCell™ (Bioheart) ..................................................................................... 70
   Transplantation of endothelial progenitor cells for revascularization of heart .... 71

Devices for cardiovascular drug delivery ....................................................... 39

   Local drug delivery by catheters .................................................................. 40
   Microneedle for periarterial injection ............................................................. 41
   Nanotechnology-based devices for the cardiovascular system ..................... 42
   Liposomal nanodevices for targeted cardiovascular drug delivery ............... 42
   Nanotechnology approach to the problem of “vulnerable plaque” ............... 42

Drug delivery in the management of cardiovascular disease .......................... 43

   Drug delivery in the management of hypertension ........................................ 43
   Transnasal drug delivery for hypertension .................................................... 44
   Transdermal drug delivery for hypertension ................................................ 44
   Oral extended and controlled release preparations for hypertension .......... 44
   Long-acting hypertensives for 24 h blood pressure control ......................... 45
   Drug delivery to control early morning blood pressure peak ...................... 45
   Role of drug delivery in improving compliance with antihypertensive therapy 46
   Vaccines for hypertension ............................................................................ 46
   Drug delivery in the treatment of angina pectoris ......................................... 47
   Sustained and controlled-release nitrate for angina pectoris ......................... 47
   Transdermal nitrate therapy .......................................................................... 47
   Controlled release calcium blockers for angina pectoris .............................. 48
   Sustained-release formulation of ranolazine ................................................ 49
   DDS in the management of ischemic heart disease ....................................... 49
   Intravenous emulsified formulations of halogenated anesthetics .................. 50
   Injectable peptide nanoformers for myocardial ischemia ............................. 50
   Delivery of angiogenesis-inducing agents for myocardial ischemia ............. 50
   Drug delivery for myocardial infarction ....................................................... 51
   Drug delivery for cardioprotection ............................................................... 51
   Cardioprotection during reperfusion ............................................................ 54
   Drug delivery for congestive heart failure .................................................... 55
   Oral human brain-type natriuretic peptide ................................................... 55
   Nitric oxide-based therapies for congestive heart failure ............................ 55
   Automated drug delivery system for cardiac failure .................................. 55
   Drug delivery for cardiac rhythm disorders ............................................... 56
   Drug delivery in the management of pulmonary hypertension .................... 56
   Endothelin receptor antagonist treatment of PAH ....................................... 57
   Prostacyclin by inhalation ............................................................................. 57
   Treprostinil .................................................................................................... 57
   Anticoagulation in cardiovascular disease .................................................... 57
   Oral heparin .................................................................................................... 58
   Low molecular weight heparin-loaded polymeric nanoparticles .................. 58
   Transdermal anticoagulants ......................................................................... 58
   Thrombolysis for cardiovascular disorders ................................................ 59
   Use of ultrasound to facilitate thrombolysis ................................................ 59
   Delivery of alteplase through the AngioJet rheolytic catheter ....................... 59
   Drug delivery for peripheral arterial disease .............................................. 59
   Delivery of thrombolytic agent to the clot through a catheter ...................... 60
   Delivery of growth factors to promote angiogenesis in ischemia .................. 60
   Immune modulation therapy for PAD ......................................................... 60
   NO-based therapies for peripheral arterial disease ..................................... 61
   Drug delivery in the management of hypercholesterolemia ......................... 61
   Controlled/sustained release formulations of statins .................................... 61
   Combinations of statins with other drugs to increase efficacy ...................... 62
   Controlled release fenofibrate ...................................................................... 63
   Extended release nicotinic acid .................................................................... 63
   Intravenous infusion of lipoprotein preparations to raise HDL ...................... 64
   Innovative approaches to hypercholesterolemia ......................................... 65
   Therapeutic antagonism of ANGPTL3 gene ............................................... 65
   Vaccines for lowering cholesterol by targeting PCSK9 ................................ 67
   Single dose therapy for more than one cardiovascular disorder ................. 67

3. Cell Therapy for Cardiovascular Disorders .................................................. 68

   Introduction .................................................................................................. 68
   Inducing the proliferation of cardiomyocytes ............................................... 68
   Role of stem cells in repair of the heart .............................................................. 68
   Cell-mediated immune modulation for chronic heart disease ...................... 68
   Cell therapy for atherosclerotic coronary artery disease .............................. 69
   Transplantation of myoblasts for myocardial infarction ............................... 69
   MyoCell™ (Bioheart) ..................................................................................... 70
   Transplantation of endothelial progenitor cells for revascularization of heart .... 71

Methods of delivery of cells to the heart .......................................................... 71
4. Gene Therapy for Cardiovascular Disorders

Introduction

Techniques of gene transfer to the cardiovascular system

Direct plasmid injection into the myocardium

Catheter-based systems for vector delivery

Ultrasound microbubbles for cardiovascular gene delivery

Vectors for cardiovascular gene therapy

AAV vectors for therapeutic delivery to the heart

Adenoviral vectors for cardiovascular diseases

Plasmid DNA-based delivery in cardiovascular disorders

Hypoxia-regulated gene therapy for myocardial ischemia

Angiogenesis and gene therapy of ischemic disorders

Therapeutic angiogenesis vs. vascular growth factor therapy

Gene painting for delivery of targeted gene therapy to the heart

Gene delivery to vascular endothelium

Overexpression of eNOS to improve vasodilation with Ad vectors

Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles

Genes therapy for genetic cardiovascular disorders

Genetic disorders predisposing to atherosclerosis

Familial hypercholesterolemia

Apolipoprotein E deficiency

Hypertension

Genetic factors for myocardial infarction

Acquired cardiovascular diseases

Coronary artery disease with angina pectoris

AdSFGF-4

Ischemic heart disease with myocardial infarction

Angiogenesis for cardiovascular disease

Myocardial repair with IGF-1 therapy

miRNA gene therapy for ischemic heart disease

Congestive heart failure

Rationale of gene therapy in CHF

AAV-mediated gene transfer for CHF

AngioCell gene therapy for CHF

P-ARKct gene therapy

Elevating cardiac dATP by gene therapy to improve cardiac function
5. Drug-Eluting Stents ..............................................116

Introduction ................................................................116

Percutaneous transcatheter coronary angioplasty ........116
Stents ........................................................................116

Restenosis .................................................................116

Pathomechanism .......................................................117
Treatment .................................................................117

Nitric oxide-based therapies for restenosis ............118
Carbon monoxide inhalation for preventing restenosis 118

Antisense approaches for prevention of restenosis after angioplasty 119

Gene therapy to prevent restenosis after angioplasty 119

Delivery of gene therapy for restenosis ......................119

HSV-1 gene therapy to prevent intimal hyperplasia 119

miRNA-based gene therapy for restenosis following angioplasty 120

Nonviral gene therapy to prevent intimal hyperplasia 120

NOS gene therapy for therapy for restenosis ................120

Targets for gene therapy of restenosis .....................121

Viral vector-mediated gene therapy for restenosis ........122

Drug delivery devices for restenosis .........................123

Local drug delivery by catheter .................................123

Stenosis associated with stents ..................................124

Absorbable metal stents .............................................124

Drug-eluting stents ..................................................124

Various types of DES ..............................................125

CYPHER® sirolimus-eluting coronary stent ................125
Dexamethasone-eluting stents ..................................125

NO-generating stents ..............................................126

Paclitaxel-eluting stents ..........................................126

Sirolimus-eluting stents ...........................................126

Novel technologies for DES .....................................127

Bio-absorbable DES .................................................127

Drug-eluting stents coated with polymer surfaces ....128

Endeavour DES .......................................................128

Polymer-free drug-coated stent for patients at high risk of bleeding 129

Stents for delivery of gene therapy ............................130

Stem cell-based stents .............................................130

VAN 10-4 DES .........................................................131

Nanotechnology-based stents ....................................131

Antisense therapy for cardiovascular disorders .......108

Antisense therapy for hypertension .........................109

Antisense therapy for hypercholesterolemia ............109

Mipomersen ............................................................109

Antisense oligonucleotides targeting ANGPTL3 .........110

siRNAs targeting PCSK9 ...........................................110

RNAi for cardiovascular disorders .........................110

RNAi for hypercholesterolemia ...............................111

siRNAs targeting PCSK9 .........................................111

MicroRNA and the cardiovascular system ................111

Role of miRNAs in angiogenesis ................................112

Role of miRNAs in cardiac hypertrophy and failure ....112

Role of miRNAs in conduction and rhythm disorders of the heart 113

miRNA-based approach for reduction of hypercholesterolemia 113

miRNAs as therapeutic targets for cardiovascular diseases 113

Future prospects of miRNA in the cardiovascular therapeutics 114

Future prospects of gene therapy of cardiovascular disorders 114

Companies involved in gene therapy of cardiovascular disorders 115

Intracoronary adenovirus-mediated gene therapy for CHF ........................................103

nNOS gene transfer in CHF ......................................103

Gene therapy for cardiac arrhythmias ......................103

Gene transfer for biological pacemakers ................104

Management of arrhythmias due to myoblast transplantation 104

Genetically engineered cells as biological pacemakers 105

Cholesterol reduction by genetic engineering of PCSK9 gene 105

Gene therapy and heart transplantation ....................106

Angiogenesis by gene therapy ................................106

HIF-1α gene therapy for peripheral arterial disease ....106

HGF gene therapy for peripheral arterial disease ......107

Ischemic neuropathy secondary to peripheral arterial disease 107

Maintaining vascular patency after surgery ..............108

Micrometrinology by catheter ................................108

Nonviral gene therapy to prevent intimal hyperplasia 108

Antisense approaches for prevention of restenosis after angioplasty 109

miRNAs in conduction and rhythm disorders of the heart 109

miRNAs in cardiac hypertrophy and failure ..............110

miRNAs in angiogenesis ..........................................110

miRNAs in conduction and rhythm disorders of the heart 111

miRNAs as therapeutic targets for cardiovascular diseases 111

Future prospects of miRNA in the cardiovascular therapeutics 112

Cholesterol reduction by genetic engineering of PCSK9 gene 112

Gene therapy for restenosis following angioplasty ....112

Restenosis ...............................................................113

Drug delivery devices for restenosis ..........................113

Local drug delivery by catheter .................................114

Stenosis associated with stents ..................................115

Absorbable metal stents .............................................115

Drug-eluting stents ..................................................116

Various types of DES ..............................................116

CYPHER® sirolimus-eluting coronary stent ................117
Dexamethasone-eluting stents ..................................117

NO-generating stents ..............................................118

Paclitaxel-eluting stents ..........................................118

Sirolimus-eluting stents ...........................................118

Novel technologies for DES .....................................120

Bio-absorbable DES .................................................120

Drug-eluting stents coated with polymer surfaces ....120

Endeavour DES .......................................................120

Polymer-free drug-coated stent for patients at high risk of bleeding 121

Stents for delivery of gene therapy ............................121

Stem cell-based stents .............................................122

VAN 10-4 DES .........................................................123

Nanotechnology-based stents ....................................123

Antisense therapy for cardiovascular disorders .......108

Antisense therapy for hypertension .........................109

Antisense therapy for hypercholesterolemia ............109

Mipomersen ............................................................109

Antisense oligonucleotides targeting ANGPTL3 .........110

siRNAs targeting PCSK9 ...........................................110

RNAi for cardiovascular disorders .........................110

RNAi for hypercholesterolemia ...............................111

siRNAs targeting PCSK9 .........................................111

MicroRNA and the cardiovascular system ................111

Role of miRNAs in angiogenesis ................................112

Role of miRNAs in cardiac hypertrophy and failure ....112

Role of miRNAs in conduction and rhythm disorders of the heart 113

miRNA-based approach for reduction of hypercholesterolemia 113

miRNAs as therapeutic targets for cardiovascular diseases 113

Future prospects of miRNA in the cardiovascular therapeutics 114

Future prospects of gene therapy of cardiovascular disorders 114

Companies involved in gene therapy of cardiovascular disorders 115

5. Drug-Eluting Stents ..............................................116

Introduction ................................................................116

Percutaneous transcatheter coronary angioplasty ........116
Stents ........................................................................116

Restenosis .................................................................116

Pathomechanism .......................................................117
Treatment .................................................................117

Nitric oxide-based therapies for restenosis ............118
Carbon monoxide inhalation for preventing restenosis 118

Antisense approaches for prevention of restenosis after angioplasty 119

Gene therapy to prevent restenosis after angioplasty 119

Delivery of gene therapy for restenosis ......................119

HSV-1 gene therapy to prevent intimal hyperplasia 119

miRNA-based gene therapy for restenosis following angioplasty 120

Nonviral gene therapy to prevent intimal hyperplasia 120

NOS gene therapy for therapy for restenosis ..............120

Targets for gene therapy of restenosis .....................121

Viral vector-mediated gene therapy for restenosis ........122

Drug delivery devices for restenosis .........................123

Local drug delivery by catheter .................................123

Stenosis associated with stents ..................................124

Absorbable metal stents .............................................124

Drug-eluting stents ..................................................124

Various types of DES ..............................................125

CYPHER® sirolimus-eluting coronary stent ................125
Dexamethasone-eluting stents ..................................125

NO-generating stents ..............................................126

Paclitaxel-eluting stents ..........................................126

Sirolimus-eluting stents ...........................................126

Novel technologies for DES .....................................127

Bio-absorbable DES .................................................127

Drug-eluting stents coated with polymer surfaces ....128

Endeavour DES .......................................................128

Polymer-free drug-coated stent for patients at high risk of bleeding 129

Stents for delivery of gene therapy ............................130

Stem cell-based stents .............................................130

VAN 10-4 DES .........................................................131

Nanotechnology-based stents ....................................131
Drugs encapsulated in biodegradable nanoparticles .................................................. 131
Magnetic nanoparticle-coated DES ........................................................................ 131
Magnetic nanoparticles encapsulating paclitaxel targeted to stents ...................... 133
Nanocoated DES ...................................................................................................... 133
Nanopores to enhance compatibility of DES ......................................................... 134
Paclitaxel-encapsulated targeted lipid-polymeric nanoparticles .......................... 134
The ideal DES .......................................................................................................... 134
Companies developing drug-eluting stents ............................................................ 135
Clinical trials of drug-eluting stents ....................................................................... 136
Measurements used in clinical trials of DES ......................................................... 136
TAXUS paclitaxel-eluting stents ............................................................................. 136
XIENCE™ V everolimus-eluting coronary stent .................................................... 137
COSTAR II clinical trial ......................................................................................... 138
Endeavor RESOLUTE zotarolimus-eluting stent system ....................................... 138
CUSTOM I clinical trial ......................................................................................... 139
NOBORI CORE Trial ............................................................................................... 139
LEADERS trial ......................................................................................................... 140
Comparison of DES releasing either zotarolimus or everolimus ....................... 140
Comparison of DES versus bare metal stents in clinical trials ............................. 140
Bioresorbable vs drug-eluting metallic stents ......................................................... 143
Multi-Link Vision bare metal stent vs DES ........................................................... 144
Guidelines for DES vs BMS .................................................................................. 144
DES vs BMS for off-label indications ..................................................................... 144
Role of DES in cases of bare-metal in-stent restenosis ........................................ 145
Comparison of revascularization methods for stable coronary disease ................ 145
DES versus coronary artery bypass graft .............................................................. 145
DES versus balloon catheter coated with paclitaxel ............................................. 146
DES versus intracoronary radiation therapy for recurrent stenosis ..................... 146
PCI plus DES as the preferred method for treatment of MI ................................... 147
Cost-effectiveness of DES ..................................................................................... 147
Safety issues of DES ............................................................................................. 148
Adverse reactions to DES ..................................................................................... 148
Long-term safety studies of DES .......................................................................... 149
Endothelial vascular dysfunction due to sirolimus .............................................. 150
Risk of clotting with DES .................................................................................... 150
Effect of blood clot on release of drug from DES ................................................. 151
Measures to prevent clotting associated with DES ............................................. 152
Clopidogrel use and long-term outcomes of patients receiving DES ................. 152
Cangrelor for platelet inhibition to prevent stent thrombosis ................................. 152
Prasugrel as antplatelet agent ................................................................................ 152
Use of magnetized cell lining to prevent clotting of DES .................................... 153
Regulatory issues of DES ....................................................................................... 153
Approved drug-eluting stents .............................................................................. 153
Safety issues of drug-eluting stents ...................................................................... 154
Assessment of efficacy of various drug-eluting stents ........................................ 155
Future prospects of treatment of restenosis by DES .......................................... 155
Effect of stent cost on clinical applications ............................................................ 155
Future role of DES in the management of cardiovascular disease ..................... 156
Improvements in stent technology ........................................................................ 156
Biodegradable stent ............................................................................................... 157
DES vs drug-eluting balloons .............................................................................. 157

6. Markets for Cardiovascular Drug Delivery ......................................................... 158

Introduction ........................................................................................................... 158
Epidemiology of cardiovascular disease ................................................................. 158
Cost of care of cardiovascular disorders ................................................................. 159
Cardiovascular markets according to important diseases ..................................... 160
Antithrombotics ..................................................................................................... 160
Anticholesterol agents .......................................................................................... 160
Antihypertensive agents ......................................................................................... 161
Drugs for congestive heart failure .......................................................................... 161
Markets for innovative technologies for cardiovascular disorders .................. 161
Markets for cell therapy of cardiovascular disorders ............................................ 161
Markets for gene therapy of cardiovascular disorders .......................................... 162
Markets for drug-eluting stents .............................................................................. 162
Major players in DES market ................................................................................ 162
Impact of safety issues on future markets for DES ............................................. 162
DES market in Asia ............................................................................................... 163
Patenting and legal issues of DES ......................................................................... 164
The financial impact of DES on cardiovascular market ........................................ 164
Unmet needs for cardiovascular drug delivery .................................................... 165
Role of DDS in developing cardiovascular markets .................................................. 165
Markets for cardiovascular devices ........................................................................... 166
Marketing of innovative cardiovascular drug delivery devices ............................... 166
Direct to consumer advertising of DES ....................................................................... 166
Future trends in the integration of drug delivery with therapeutics ......................... 167
Future of cardiovascular drug delivery ...................................................................... 167

7. Companies involved in Cardiovascular Drug Delivery ................................. 168
Profiles of companies ................................................................................................. 168
Collaborations ............................................................................................................. 257

8. References ............................................................................................................... 261

Tables

Table 1-1: Landmarks in the historical evolution of cardiovascular drug delivery .......... 12
Table 1-2: Approaches to management of myocardial infarction and its sequence ....... 13
Table 1-3: Gene polymorphisms that alter cardiovascular response to drugs .......... 18
Table 2-1: Routes of drug delivery used for treatment of cardiovascular disorders .... 26
Table 2-2: Formulations for drug delivery to the cardiovascular system ................. 28
Table 2-3: Monoclonal antibodies used for cardiovascular disorders ..................... 33
Table 2-4: Improved methods of systemic drug delivery of cardiovascular drugs .... 35
Table 2-5: Targeted delivery of therapeutic substances to the cardiovascular system . 38
Table 2-6: Classification of devices for drug delivery to the cardiovascular system .... 39
Table 2-7: Various methods of delivery of therapeutic agents for hypertension ....... 43
Table 2-8: Marketed controlled/extended release preparation for hypertension ....... 45
Table 2-9: Methods of delivery of nitrate therapy in angina pectoris ....................... 47
Table 2-10: Drug delivery in ischemic heart disease ............................................... 49
Table 2-11: Strategies for cardioprotection ................................................................. 52
Table 2-12: Drug delivery for peripheral arterial disorders ..................................... 60
Table 3-1: Clinical trials of cell therapy in cardiovascular disease ......................... 80
Table 4-1: Cardiovascular disorders for which gene therapy is being considered ........ 88
Table 4-2: Catheter-based systems for vector delivery to the cardiovascular system . 89
Table 4-3: Potential applications of antisense in cardiovascular disorders .............. 109
Table 4-4: Companies involved in gene therapy of cardiovascular diseases ............ 115
Table 5-1: Treatment of restenosis ................................................................................. 117
Table 5-2: Devices used for drug delivery in restenosis ............................................ 123
Table 5-3: Companies involved in drug-eluting stents ............................................. 135
Table 5-4: Drug-eluting stents approved by the FDA ................................................ 153
Table 6-1: Prevalence of cardiovascular disorders in major markets: US 2018-2028 .... 159
Table 6-2: Prevalence of cardiovascular disorders in major markets: Europe 2018-2028 .... 159
Table 6-3: Prevalence of cardiovascular disorders in major markets: Japan 2018-2028 .... 159
Table 6-4: Values of cardiovascular DDS in major markets 2018-2028 ................. 160
Table 6-5: Markets for innovative technologies for cardiovascular disorders 2018-2028 .... 161
Table 7-1: Top 5 companies in cardiovascular drug delivery .................................... 168
Table 7-2: Collaborations in cardiovascular drug delivery ...................................... 257

Figures

Figure 1-1: Drug delivery, biotechnology and cardiovascular diseases .................. 22
Figure 2-1: MicroSyringe for periarterial injection ................................................. 41
Figure 2-2: Patch for delivery of follistatin-like 1 factor for myocardial infarction ...... 52
Figure 2-3: Lipoprotein metabolism in ANGPTL3 deficiency ................................. 66
Figure 5-1: Vicious circle of vascular occlusion following angioplasty and stenting . 118
Figure 5-2: Measurement of in-stent stenosis ......................................................... 124
Figure 5-3: Medtronic’s Endeavour drug-eluting stent ........................................... 129
Figure 5-4: Magnetic nanoparticle-coated stent ...................................................... 133
Figure 6-1: Unmet needs for cardiovascular drug delivery ....................................... 165
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE</td>
<td>angiotensin-converting enzyme</td>
</tr>
<tr>
<td>CAD</td>
<td>coronary artery disease</td>
</tr>
<tr>
<td>CHF</td>
<td>congestive heart failure</td>
</tr>
<tr>
<td>CR</td>
<td>controlled release</td>
</tr>
<tr>
<td>CVS</td>
<td>cardiovascular system</td>
</tr>
<tr>
<td>DDS</td>
<td>drug delivery system</td>
</tr>
<tr>
<td>DES</td>
<td>drug-eluting stent</td>
</tr>
<tr>
<td>eNOS</td>
<td>endothelial nitric oxide synthase</td>
</tr>
<tr>
<td>EPC</td>
<td>endothelial progenitor cells</td>
</tr>
<tr>
<td>HDL</td>
<td>high-density lipoprotein</td>
</tr>
<tr>
<td>hESCs</td>
<td>human embryonic stem cells</td>
</tr>
<tr>
<td>HSCs</td>
<td>hematopoietic stem cells</td>
</tr>
<tr>
<td>IHD</td>
<td>ischemic heart disease</td>
</tr>
<tr>
<td>LDL</td>
<td>low-density lipoprotein</td>
</tr>
<tr>
<td>NIH</td>
<td>Nation Institutes of Health, USA</td>
</tr>
<tr>
<td>NO</td>
<td>nitric oxide</td>
</tr>
<tr>
<td>NOS</td>
<td>nitric oxide synthase</td>
</tr>
<tr>
<td>PAD</td>
<td>peripheral arterial disease</td>
</tr>
<tr>
<td>PEG</td>
<td>poly(ethylene glycol)</td>
</tr>
<tr>
<td>PTCA</td>
<td>percutaneous transluminal coronary angioplasty</td>
</tr>
<tr>
<td>RNAi</td>
<td>RNA interference</td>
</tr>
<tr>
<td>SC</td>
<td>stem cell</td>
</tr>
<tr>
<td>siRNA</td>
<td>short interfering RNAs</td>
</tr>
<tr>
<td>VEGF</td>
<td>vascular endothelial growth factor</td>
</tr>
</tbody>
</table>